Rapid Medical’s Tigertriever Introduced in United States to Treat Ischemic Stroke

May 5, 2021—Rapid Medical announced that the first patients in the United States have been treated with the company’s FDA-cleared Tigertriever revascularization device. The cases were performed by Rishi Gupta, MD, Director of Neurocritical Care at Wellstar Health System in Marietta, Georgia.

According to the company, Tigertriever is an adjustable stent retriever, enabling neurointerventionalists to remove blood clots and restore blood flow to the brain after an ischemic event. The device is available in the United States in 21- and 17-mm sizes and is applicable for a wide range of large vessel occlusions.

“With Tigertriever, I can adjust the sizing of the device to more safely engage and retrieve the blood clot,” commented Dr. Gupta in Rapid Medical’s announcement. “Additionally, the Tigertriever 17 device has the smallest diameter of any clot retriever, allowing me to treat occlusions further in the brain. This new class of mechanical thrombectomy devices shows significant clinical potential for the treatment of stroke.”

The company announced FDA clearance of the device in March 2021. Also in March, the company announced the publications of the TIGER trial, which supported FDA clearance. Rapid Medical stated that the trial documented Tigertriever’s superiority over conventional stent retrievers, achieving a statistically significant improvement in the ability to restore blood flow to the brain and excellent comparable safety metrics. Even in the smaller, more difficult to treat brain vessels, Tigertriever 17 achieved 92% revascularization success, noted the company.